{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:08:54Z","timestamp":1773317334223,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T00:00:00Z","timestamp":1433462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0128208","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T15:03:42Z","timestamp":1433516622000},"page":"e0128208","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Development of Sustained Release \u201cNanoFDC (Fixed Dose Combination)\u201d for Hypertension \u2013 An Experimental Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Anjuman","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. K.","family":"Khuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Special communication: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"ref2","first-page":"91","article-title":"Hypertension Guidelines: Revisiting the JNC 7 Recommendations","volume":"3","author":"J Martin","year":"2008","journal-title":"The Journal of Lancaster General Hospital"},{"key":"ref3","unstructured":"The World Health Statistics Report 2012; Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/44844\/1\/9789241564441_eng.pdf?ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/44844\/1\/9789241564441_eng.pdf?ua=1<\/ext-link>"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1586\/erc.10.115","article-title":"Valsartan\u2013amlodipine\u2013hydrochlorothiazide: the definitive fixed combination?","volume":"8","author":"V Barrios","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"Suppl. 1","key":"ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/1159615-s0-000000000-00000","article-title":"Modern Clinical Management of Arterial Hypertension. Fixed or Free Combination Therapies?","volume":"18","author":"G Tocci","year":"2011","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"2007. ESH\u2013ESC Practice Guidelines for the Management of Arterial Hypertension: ESH\u2013ESC Task Force on the Management of Arterial Hypertension","volume":"25","author":"G Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"AV Chobanian","year":"2003","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0828-282X(10)70379-2","article-title":"The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2\u2014therapy","volume":"26","author":"DG Hackam","year":"2010","journal-title":"Can J Cardiol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0975-7406.129175","article-title":"Barriers to and determinants of medication adherence among hypertensive patients attended National Health Service Hospital, Sunderland","volume":"6","author":"MU Khan","year":"2014","journal-title":"Journal of Pharmacy and Bioallied Sciences"},{"key":"ref10","first-page":"1","article-title":"Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population","author":"SA Baggarly","year":"2014","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"ref11","article-title":"Formulation for the prevention of cardiovascular disease","author":"NJ Wald","year":"2004","journal-title":"UK patent GB2361186"},{"key":"ref12","first-page":"1","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"NJ Wald","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajps.2013.12.005","article-title":"A promising choice in hypertension treatment: Fixed-dose combinations","volume":"9","author":"X Wan","year":"2014","journal-title":"Asian Journal of Pharmaceuticsl Sciences"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00129784-200808010-00006","article-title":"Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine\/benazepril versus component-based free-combination therapy","volume":"8","author":"M. Dickson","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpcardio1419","article-title":"Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population","volume":"6","author":"G Sanz","year":"2009","journal-title":"nature clinical practice cardiovascular medicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/967073","article-title":"The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis","volume":"2014","author":"KA. Galen","year":"2014","journal-title":"AIDS Research and Treatment"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4236\/jbnb.2012.31007","article-title":"Multi-drug delivery systems with single formulation\u2014current status and future perspectives","volume":"3","author":"T Okuda","year":"2012","journal-title":"Journal of Biomaterials and Nanobiotechnology"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2217\/fon.11.109","article-title":"Nanoscale delivery systems for multiple drug combinations in cancer","volume":"7","author":"Y Cao","year":"2011","journal-title":"Future Oncol"},{"key":"ref19","first-page":"459","article-title":"Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications","volume":"44","author":"R Pandey","year":"2006","journal-title":"Indian J Exp Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10717544.2010.509367","article-title":"Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system management of multi-drug resistant tuberculosis","volume":"18","author":"G Kumar","year":"2011","journal-title":"Drug Delivery"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/jps.23087","article-title":"Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation","volume":"101","author":"G Kumar","year":"2012","journal-title":"J Pharm Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of variable drug loaded bio degradable poly (lactic-co-glycolic) acid (PLGA) devices","volume":"21","author":"RA. Jain","year":"2000","journal-title":"Biomaterials"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/03639049809082719","article-title":"Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches","volume":"24","author":"R Jain","year":"1998","journal-title":"Drug Dev Indus Pharm"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2174\/1573413710666140512221814","article-title":"Development of Sustained Release \u201cNanopolypill\u201d of Ischemic Heart Disease Drugs\u2014An Experimental Study","volume":"10","author":"A Arora","year":"2014","journal-title":"CNANO"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0378-5173(99)00046-0","article-title":"Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly (DL-lactide-co-glycolide) microspheres","volume":"183","author":"J Rojas","year":"1999","journal-title":"Int J Pharm"},{"key":"ref26","first-page":"894","article-title":"single RP-HPLC method for the determination of hydrochlorothiazide, amlodipine and Valsartan in pharmaceutical products","volume":"4","author":"KR Ullavapally","year":"2011","journal-title":"Journal of Pharmacy Research"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10717544.2010.509367","article-title":"Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system management of multi-drug resistant tuberculosis","volume":"18","author":"G Kumar","year":"2011","journal-title":"Drug Delivery"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s11095-008-9560-0","article-title":"What is suitable dissolution method for drug nanoparticles?","volume":"25","author":"D Heng","year":"2008","journal-title":"Pharmaceutical research"},{"key":"ref29","unstructured":"US-FDA Guidance for Industry for Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 2005 Pharmacology and Toxicology. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm078932.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm078932.pdf<\/ext-link> Accessed 2012 July 12."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.jhh.1001722","article-title":"Compliance with pharmacological therapy in hypertension: can we do better, and how?","volume":"18","author":"G Thrall","year":"2004","journal-title":"Journal of Human Hypertension"},{"key":"ref31","first-page":"173","article-title":"Improved bioavailability of orally administered mifepristone from PLGA nanoparticles","volume":"34","author":"H Weiling","year":"2007","journal-title":"Int J Pharm"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jconrel.2007.02.004","article-title":"PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral","volume":"119","author":"JL Italia","year":"2007","journal-title":"J Contr Rel"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157341309787314566","article-title":"Poly (lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins","volume":"5","author":"Magdalena Stevanovi","year":"2009","journal-title":"Current Nano Sciences"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0128208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T03:25:49Z","timestamp":1566789949000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0128208"}},"subtitle":[],"editor":[{"given":"Toshiaki","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,5]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0128208","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,5]]}}}